TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03710447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT + WB-EMS
Description: 12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and whole-body electromyostimulation (WB-EMS).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~2 exercise sessions per week. Order of application: HIIT - WB-EMS. Additionally, participants receive individualized nutritional counseling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-EMS + HIIT
Description: 12-week supervised exercise program consisting of whole-body electromyostimulation (WB-EMS) and ergometer-based high-intensity interval training (HIIT).~WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: WB-EMS - HIIT. Additionally, participants receive individualized nutritional counseling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT + CST
Description: 12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and conventional low-volume strength training(CST).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~2 exercise sessions per week. Order of application: HIIT - CST. Additionally, participants receive individualized nutritional counseling.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CST + HIIT
Description: 12-week supervised exercise program consisting of conventional low-volume strength training(CST) and ergometer-based high-intensity interval training (HIIT).~CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: CST - HIIT. Additionally, participants receive individualized nutritional counseling.
Study: NCT03882424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRS003
Description: 25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: China-approved Bevacizumab
Description: 25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Avastin
Description: 25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
Study: NCT00947284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine plus naloxone
Description: single dose administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine plus naloxone
Description: single dose administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine plus saline
Description: single dose administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine plus saline
Description: single dose administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone plus saline
Description: single dose administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone plus saline
Description: single dose administered intravenously
Study: NCT04172285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Home-based physical activity program

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Physical activity and supplementation
Description: Home-based physical activity program and amminoacid supplementation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention
Study: NCT01417754

Intervention type: DRUG
Group type: OTHER
Intervention: Toremifene
Description: 20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
Study: NCT01953744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine Antimoniate
Description: Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
Study: NCT03404999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical decision support
Description: Decision support system (see description of hypertension decision support system alerts and order sets for details)
Study: NCT02427113

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sound Oasis Vibrating Chair
Description: Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Select Music
Description: The self-select music of the participants will be applied for managing the painful symptoms of TMD
Study: NCT03839108

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin wax
Description: Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: . Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
Study: NCT02432352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Our Family Our Future
Description: The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
Study: NCT04130308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrun to run protocol
Description: Progressive return to run protocol for patients after ACL-R
Study: NCT00566384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone, BAY86-5314
Description: Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
Study: NCT02830386

Intervention type: DEVICE
Intervention: LVIS stent
Description: Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
Study: NCT02950792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViewRay MRI
Description: ViewRay Magnetic Resonance Imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy Boost
Description: In the (week 5), all patients will have a week 5 MRI and Four-dimensional computed tomography (4D CT) for purposes of planning Phase II boost. Gross tumors \< 5 cm will receive a MR-based adaptive replanning Stereo boost of 80 Gy - 90 Gy (20 Gy-30 Gy in 5 fractions). Gross tumors \< 5cm will receive an MR-based adaptive replan fractionated boost to 74 Gy at 2.4 Gy/day. Individualized radiation therapy prescription to primary tumor will maintain organs at risk (OAR) constraints to lung including mean lung dose (MLD) \< 20 Gy with V20 \< 37%. Simultaneously, MRI-based adaptive replanning boost of 12 Gy in 5 fractions (2.4 Gy/day) will be given to gross lymph nodes. Final doses prescribed will be limited by doses to all OARs.
Study: NCT01598376

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 7/0 vicryl suture
Description: 7/0 vicryl test suture placed as one of 3 everting sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5/0 vicryl test suture
Description: 5/0 vicryl test suture placed as one of 3 everting sutures
Study: NCT01672931

Intervention type: OTHER
Intervention: Oocyte Measurement
Study: NCT02717390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright By Three (BB3)
Description: The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Texts for Child Safety (TCS)
Description: The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety \[TCS\]) among participants in the injury prevention arm with those randomized to the BB3 arm.
Study: NCT04407962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS group
Description: The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
Study: NCT02804945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: Participants receive a maximum dose of 3 x 10\^6 cell/Kg by vein one time on Day 1.
Study: NCT01604694

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP Block
Description: An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
Study: NCT01248247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth each day of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: 100 mg by mouth daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: 100 mg by mouth every week of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg by mouth twice a day for a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: 135 mg by mouth every week of a 28 day cycle.
Study: NCT01940094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Prednisone
Description: Subjects will remain on daily prednisone dose of 5 mg
Study: NCT00455117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Parecoxib ('Dynastat' Pfizer)
Description: parecoxib or placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Parecoxib ('Dynastat' Pfizer)
Description: parecoxib or placebo
Study: NCT04566367

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blue laser imaging
Description: The intervention is the push on demand activation of blue laser imaging technique during gastroscopy.
Study: NCT01940094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 mg Prednisone
Description: Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
Study: NCT03033576

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01269593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET Imaging using 124 IPUH71
Description: A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (\~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
Study: NCT03375320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study: NCT03069924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-framed messaging
Description: Gain-framed messaging materials

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Unframed messaging materials
Description: Unframed smoking cessation materials
Study: NCT03232008

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Canderel drink
Description: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Canderel+Lyle's Golden Syrup drink
Description: Canderel: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water Lyle's Golden Syrup: 35 g (27g of glucose and fructose)
Study: NCT05110209

Intervention type: OTHER
Intervention: Aflibercept
Description: intravitreal injection

Intervention type: OTHER
Intervention: Ranibizumab
Description: intravitreal injection

Intervention type: OTHER
Intervention: Bevacizumab
Description: intravitreal injection
Study: NCT02935686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Ad26.Mos4.HIV at a dose of 5\*10\^10 viral particles (vp), administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Ad26.Mos4.HIV at a dose of 5\*10\^10 viral particles (vp), administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Ad26.Mos4.HIV at a dose of 5\*10\^10 viral particles (vp), administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140 plus adjuvant
Description: Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140/Mosaic gp140 plus adjuvant
Description: Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Containing 0.9 percent normal saline, administered intramuscularly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Containing 0.9 percent normal saline, administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp140 HIV Bivalent Vaccine
Description: gp140 HIV Bivalent Vaccine is adjuvanted protein co-formulation with a dosage strength of 80 mcg Clade C protein, 75 mcg Mosaic protein and 425 mcg aluminum (as aluminum phosphate adjuvant).
Study: NCT01946204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: 240 mg tablets administered by mouth on a continuous once daily dosing regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
Study: NCT03038048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varying needle size with intravitreal ranibizumab or aflibercept
Description: Varying gauge of needle, 33 gauge vs 30 gauge

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Varying needle size with intravitreal ranibizumab or aflibercept
Description: Varying gauge of needle, 33 gauge vs 30 gauge
Study: NCT04165564

Intervention type: OTHER
Intervention: Institutional standard of care
Description: Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
Study: NCT04566367

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blue laser imaging
Description: The intervention is the push on demand activation of blue laser imaging technique during gastroscopy.
Study: NCT00891995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop
Description: Closed loop therapy for up to 4 to 6 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home glucose monitoring
Description: Standard diabetes management using a home glucose meter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home glucose monitoring
Description: Standard diabetes management using a home glucose meter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Insulin pump use for 2 years

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Continuous glucose monitor use for 2 years
Study: NCT02859155

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Multivisceral en bloc resection surgery
Description: Multivisceral en bloc resection for colorectal cancer in advance patients (T4)
Study: NCT03472508

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Folic Acid
Description: Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
Study: NCT04165564

Intervention type: OTHER
Intervention: Institutional standard of care
Description: Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)

Intervention type: OTHER
Intervention: Biosamples of airway and blood
Description: Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.

Intervention type: OTHER
Intervention: Biosamples of airway and blood
Description: Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
Study: NCT02330068

Intervention type: DRUG
Intervention: citalopram
Description: Cases
Study: NCT02209480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alexander Technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heat pad application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: guided imagery
Study: NCT00153803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (tarceva)
Description: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.